10:57 AM EST, 01/06/2025 (MT Newswires) -- Spectral Medical ( EDTXF ) on Monday said it has enrolled 140 patients for its Tigris trail, a phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (PMX) in a randomized controlled trial of adults treated for endotoxemia and septic shock.

Enrollment improved in December as issues related to the production of critical intravenous fluids started to ease. Spectral is projecting full enrollment for the Tigris trial by the end of the first quarter.

"We view December as a transitional month from an enrollment perspective, as the medical supply chain issues eased," Chief Medical Officer Dr John Kellum said. "Given the continued strong engagement and enthusiasm at our Tigris sites, we anticipate a return to a more normalized enrollment rate in the new year."

Spectral was last seen up $0.02, to $0.57, on the Toronto Stock Exchange.

Price: 0.57, Change: +0.02, Percent Change: +3.64